Hello, good evening, sir. Thank you for the opportunity. Sir, you mentioned about multiple product launches for FY27, potentially to offset the decreasing rate of Revlimid. Can you tell me, will this be in the existing therapy area or in any new therapy areas?
All right. Got it. Thank you very much.